BR112015001521A2 - previsão de resposta ao tratamento para inibidor jak/stat - Google Patents

previsão de resposta ao tratamento para inibidor jak/stat

Info

Publication number
BR112015001521A2
BR112015001521A2 BR112015001521A BR112015001521A BR112015001521A2 BR 112015001521 A2 BR112015001521 A2 BR 112015001521A2 BR 112015001521 A BR112015001521 A BR 112015001521A BR 112015001521 A BR112015001521 A BR 112015001521A BR 112015001521 A2 BR112015001521 A2 BR 112015001521A2
Authority
BR
Brazil
Prior art keywords
jak
stat inhibitor
prediction
treatment response
stat
Prior art date
Application number
BR112015001521A
Other languages
English (en)
Inventor
Cao Alexander
Sonkin Dmitriy
Morrisey Michael
Palmer Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015001521(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015001521A2 publication Critical patent/BR112015001521A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Abstract

resumo patente de invenção: "previsão de resposta ao tratamento para inibidor jak/stat". a invenção inclui, em parte, um método de seleção de um indivíduo que tem câncer para tratamento com um inibidor de jak/stat e um método para determinar se uma dose terapeuticamente eficaz de um inibidor de jak/stat foi administrada.
BR112015001521A 2012-07-27 2013-07-24 previsão de resposta ao tratamento para inibidor jak/stat BR112015001521A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261676484P 2012-07-27 2012-07-27
US201361769271P 2013-02-26 2013-02-26
US201361829327P 2013-05-31 2013-05-31
PCT/US2013/051824 WO2014018632A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Publications (1)

Publication Number Publication Date
BR112015001521A2 true BR112015001521A2 (pt) 2017-11-07

Family

ID=48906529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001521A BR112015001521A2 (pt) 2012-07-27 2013-07-24 previsão de resposta ao tratamento para inibidor jak/stat

Country Status (18)

Country Link
US (1) US20150299796A1 (pt)
EP (1) EP2877596A1 (pt)
JP (1) JP2015526074A (pt)
KR (1) KR20150038241A (pt)
CN (1) CN104508149A (pt)
AU (2) AU2013295855A1 (pt)
BR (1) BR112015001521A2 (pt)
CA (1) CA2880198A1 (pt)
CL (1) CL2015000192A1 (pt)
HK (1) HK1205198A1 (pt)
IL (1) IL236897A0 (pt)
MX (1) MX2015001269A (pt)
PH (1) PH12015500169A1 (pt)
RU (1) RU2015106714A (pt)
SG (1) SG11201500261VA (pt)
TN (1) TN2015000019A1 (pt)
TW (1) TW201409030A (pt)
WO (1) WO2014018632A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
SG11201706756VA (en) 2015-03-10 2017-09-28 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106544414A (zh) * 2016-10-09 2017-03-29 广州泰诺迪生物科技有限公司 一种检测肺癌脑转移样本中stat3和lck的方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107137701B (zh) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US20060194275A1 (en) * 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
EP2350317A4 (en) * 2008-10-20 2012-06-27 Univ Colorado Regents BIOLOGICAL MARKERS FOR PREDICTING THE ANTICIPATE RESPONSE TO INSULINARY GROWTH FACTOR 1 RECEPTOR KINASE INHIBITORS
US8501936B2 (en) * 2009-06-05 2013-08-06 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
MX2013006261A (es) * 2010-12-03 2013-10-01 Ym Biosciences Australia Pty Tratamiento de condiciones mediadas por jak2.

Also Published As

Publication number Publication date
TN2015000019A1 (en) 2016-06-29
AU2017204894A1 (en) 2017-08-03
CA2880198A1 (en) 2014-01-30
US20150299796A1 (en) 2015-10-22
AU2013295855A1 (en) 2015-02-12
SG11201500261VA (en) 2015-02-27
HK1205198A1 (en) 2015-12-11
WO2014018632A1 (en) 2014-01-30
PH12015500169A1 (en) 2015-03-16
CL2015000192A1 (es) 2015-06-26
RU2015106714A (ru) 2016-09-20
MX2015001269A (es) 2015-05-08
IL236897A0 (en) 2015-03-31
KR20150038241A (ko) 2015-04-08
CN104508149A (zh) 2015-04-08
TW201409030A (zh) 2014-03-01
EP2877596A1 (en) 2015-06-03
JP2015526074A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112015022197A2 (pt) tratamento de cataplexia
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112013020798A2 (pt) terapia de combinação do inibidor mtor /jak
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
BR112015009746A2 (pt) Agente que aumenta atividade de glicocerebrosidase em mamíferos
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
IN2015DN00376A (pt)
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112014002141A2 (pt) crizotinib para uso no tratamento de câncer
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2524 DE 21-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.